VALTREX offers a favorable safety profile.*
In a 1-year study of daily therapy, the safety profile of VALTREX in adults was comparable to placebo for all dosages, with reported adverse events being generally mild.
| Incidence of adverse events with daily suppression | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Results from a 52-week randomized, prospective, multicenter, double-blind trial of 1479 immunocompetent patients with genital herpes who received daily VALTREX, acyclovir, or placebo. All patients enrolled had a history of 6 or more recurrences/year.
- Dosage adjustments should be made in patients with varying degrees of renal dysfunction
- Pregnancy category B
- VALTREX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
- Contact Us with any questions you may have.
*In immunocompetent adults.
